Somewhat Positive Press Coverage Somewhat Unlikely to Affect Apellis Pharmaceuticals (NASDAQ:APLS) Share Price
Press coverage about Apellis Pharmaceuticals (NASDAQ:APLS) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.8614067453094 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
NASDAQ APLS traded down $0.30 during trading on Friday, reaching $18.51. 207,341 shares of the stock traded hands, compared to its average volume of 205,255. The company has a debt-to-equity ratio of 0.12, a quick ratio of 26.02 and a current ratio of 26.02. Apellis Pharmaceuticals has a fifty-two week low of $12.45 and a fifty-two week high of $32.00.
Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, July 31st. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.14). sell-side analysts forecast that Apellis Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Featured Article: What does earnings per share mean?
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.